This issue was directly explored by Conlan and coworkers who have screened a large set of ovarian cancers, showing that SMARCA4 loss was observed in 94% of SCCOHT samples, with the exception of a rare positivity (3%) in clear cell carcinomas [174]. Here, SMARCA4 is linked to clear cell adenocarcinoma.